Atypical inflammatory bowel disease and multi‐system inflammation expand the phenotype of inhibitor of nuclear factor kappa B kinase subunit beta gain‐of‐function variants

OBJECTIVES: Gain-of-function (GoF) variants in the inhibitor of nuclear factor kappa-B kinase subunit beta (IKK2) protein, encoded by inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB), have previously been reported to cause autoinflammation with a progressive immunodeficiency. Genetic defects have not previously been described in inflammatory bowel disease (IBD), although disruption of highly interacting proteins, such as IKBKG and RELA, are known causes of monogenic IBD. METHODS: Using whole exome sequencing data, we screened a cohort of over 1250 adult and paediatric onset patients with IBD for deleterious variants (minor allele frequency < 0.0005, Combined Annotation Dependent Depletion [CADD] > 15) in IKBKB. We retrieved in-depth phenotypic data and performed peripheral blood mononuclear cell CD25/CD70 stimulation validation in patients with apparent IKBKB GoF variants. RESULTS: We identified 11 patients with potentially pathogenic variants. Correlation with clinical and immunophenotypic data prioritised a rare, potential gain-of-function, variant in a patient and his affected parent, c.522T>G, p Asp174Glu. The proband had multi-system inflammation and severe atypical inflammatory bowel disease with rectal stricturing. We demonstrated impaired CD25/CD70 T- and B-cell responses in the patient, characteristic of the IKBKB defect, alongside hallmark immunological manifestations of reduced natural killer and B-cell numbers, and perturbed immunoglobulin titres. Treatment with a selective Janus kinase (JAK1)-inhibitor resulted in rapid clinical and biochemical improvement. CONCLUSIONS: This study expands the phenotypic manifestation of IKBKB GoF variants to include IBD and demonstrates a biologically plausible targeted treatment. Further functional work is required to elucidate the precise mechanism of bowel inflammation and identify additional patients.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Gastroenterology and Nutrition
Published
2026-11-18
DOI
https://doi.org/10.1002/jpn3.70689
Primary Topic
Immunodeficiency and Autoimmune Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Atypical inflammatory bowel disease and multi‐system inflammation expand the phenotype of inhibitor of nuclear factor kappa B kinase subunit beta gain‐of‐function variants

Sarah Ennis, Zachary Green, Bhumita Vadgama, James John Ashton et al.
Journal of Pediatric Gastroenterology and Nutrition
Immunodeficiency and Autoimmune Disorders
article

Atypical inflammatory bowel disease and multi‐system inflammation expand the phenotype of inhibitor of nuclear factor kappa B kinase subunit beta gain‐of‐function variants

Sarah Ennis, Zachary Green, Bhumita Vadgama, James John Ashton, R Mark Beattie, Anthony Peter Williams, Alexander Ross, Iman Nazari, Kimberly C Gilmour, Alexandre Zacharie Kadhim, Guo Cheng, Fernando Lopez, Lynn K. Win, Mercedes Selby
article en

Abstract

OBJECTIVES: Gain-of-function (GoF) variants in the inhibitor of nuclear factor kappa-B kinase subunit beta (IKK2) protein, encoded by inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB), have previously been reported to cause autoinflammation with a progressive immunodeficiency. Genetic defects have not previously been described in inflammatory bowel disease (IBD), although disruption of highly interacting proteins, such as IKBKG and RELA, are known causes of monogenic IBD. METHODS: Using whole exome sequencing data, we screened a cohort of over 1250 adult and paediatric onset patients with IBD for deleterious variants (minor allele frequency < 0.0005, Combined Annotation Dependent Depletion [CADD] > 15) in IKBKB. We retrieved in-depth phenotypic data and performed peripheral blood mononuclear cell CD25/CD70 stimulation validation in patients with apparent IKBKB GoF variants. RESULTS: We identified 11 patients with potentially pathogenic variants. Correlation with clinical and immunophenotypic data prioritised a rare, potential gain-of-function, variant in a patient and his affected parent, c.522T>G, p Asp174Glu. The proband had multi-system inflammation and severe atypical inflammatory bowel disease with rectal stricturing. We demonstrated impaired CD25/CD70 T- and B-cell responses in the patient, characteristic of the IKBKB defect, alongside hallmark immunological manifestations of reduced natural killer and B-cell numbers, and perturbed immunoglobulin titres. Treatment with a selective Janus kinase (JAK1)-inhibitor resulted in rapid clinical and biochemical improvement. CONCLUSIONS: This study expands the phenotypic manifestation of IKBKB GoF variants to include IBD and demonstrates a biologically plausible targeted treatment. Further functional work is required to elucidate the precise mechanism of bowel inflammation and identify additional patients.

Journal of Pediatric Gastroenterology and Nutrition
Southampton Hospital (US), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), Southampton General Hospital (GB), National Institute for Health and Care Research (GB), NIHR Southampton Biomedical Research Centre (GB), Southampton Children's Hospital (GB), University of Southampton (GB)
Immunodeficiency and Autoimmune Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon